Mylan is engaged in the global development, licensing, manufacture, marketing and distribution of generic, branded generic, brand-name and over-the-counter (OTC) pharmaceutical products for resale by others and active pharmaceutical ingredients (API) through three reportable segments on a geographic basis, North America, Europe and Rest of World. Co.'s API business is conducted through its subsidiary, Mylan Laboratories Limited, which is included within its Rest of World segment. Among Co.'s branded prescription products are EpiPen® Auto-Injector, Perforomist® Inhalation Solution and Dymista®. Co.'s OTC portfolio includes Cold-EEZE®, MidNite® and Vivarin®, as well as other products. When considering the Viatris Inc stock dividend history, we have taken known splits into account, such that the MYL dividend history is presented on a split-adjusted ("apples to apples") basis. Viatris Inc dividend history is presented both in graphical/chart form, and as a MYL dividend history data table along the right-hand column.
|
MYL Stock Dividend HistoryThe MYL dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable MYL historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the MYL dividend history record. Also see the MYL stock dividend history data table along the right-hand column below. |
|
|
Buy (2.73 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: MYL Forecast Based on data provided by Zacks Investment Research via Quandl.com |